New drug combo shows promise in controlling Early-Stage leukemia

This study tests a combination of two drugs, dasatinib and venetoclax, in people with early chronic phase chronic myeloid leukemia (CML). The goal is to see if the combination can better control the disease by blocking enzymes that help cancer cells grow. About 155 participants who have received little or no prior treatment will take part. The study focuses on achieving a major molecular response, meaning very low levels of cancer-related genetic material.